Antigen Microarray Complement Activation Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current multiplex immunoprofiling assays fail to effectively detect and quantify the activation of the complement system by antigens on antigen arrays, which is crucial for understanding immune responses and diagnosing diseases, as they primarily focus on antibody binding rather than the functional consequences of antigen-serum interactions.
Innovation Solution
A method utilizing antigen microarrays with covalently bound C3 and/or C4 fragments, where the complement system is activated in a single reaction chamber, allowing for the measurement of these fragments using a labelled detecting agent, providing a qualitative and quantitative analysis of complement activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional multiplex immunoprofiling assays are used to detect antibody binding, then the assay can identify antigen-antibody interactions, but it fails to detect and quantify complement system activation
Solution Approach 1:
The assay is designed to perform multiple functions simultaneously: detecting both antibody binding and complement system activation in a single experiment. The microarray platform is enhanced to capture not only antigen-antibody interactions but also downstream complement activation events, making the assay universally applicable for comprehensive immune response profiling.
Solution Approach 2:
The detection process is segmented into distinct functional modules: (1) antigen array for capturing antibodies, (2) complement activation zone for generating C3/C4 fragments, and (3) detection system for measuring complement products. This segmentation allows each component to be optimized independently while contributing to the overall capability of detecting both binding and functional activation events.
2Loss of information
If the assay focuses on antibody binding detection, then the methodology is straightforward, but it cannot provide information on the functional consequences of antigen-serum interactions
Solution Approach 1:
The assay incorporates preliminary action by pre-equilibrating the serum sample with the antigen array under conditions that allow complement activation to occur during the incubation period. This preliminary complement activation step occurs before the actual detection phase, ensuring that functional consequences are captured without requiring separate activation experiments.
Solution Approach 2:
C3 and C4 complement proteins serve as intermediaries that bridge the gap between antibody binding and functional outcome detection. These complement components are introduced as mediators that, when activated by antigen-antibody complexes, generate detectable fragments (C3a, C3b, C4a, C4b) that provide information about the functional consequences of the immune interaction.
3Loss of time
If complement activation is measured in separate experiments, then each measurement can be optimized, but the overall process is time-consuming and lacks correlation between binding and activation
Solution Approach 1:
The assay merges antibody binding detection and complement activation measurement into a single integrated experiment. By combining these previously separate measurements into one concurrent process, the assay eliminates the time required for multiple sequential experiments while ensuring that both readings reflect the same biological interaction event, thereby improving reliability through inherent correlation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables highly specific and sensitive detection of complement activation, providing detailed immunoprofiles that aid in disease diagnosis, differential diagnosis, and personalized medical treatment by assessing antigen-specific complement deposition and antibody-dependent activation.
Implementation Method 1
allowing complement activation to take place in a single reaction chamber per sample on the microarray, resulting in localized, antigen-specific deposition of C3 and/or C4 fragments
Implementation Method 2
covalently bound C3 and/or C4 fragments are detected with a labelled detecting agent
Implementation Method 3
The antigens of the antigen array are preferably parasites, microbes, viruses, prions or components thereof
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3C
AI summary
The basis of the present invention is that antigens on an antigen array can initiate complement activation both by antibody-dependent or -independent way. The systems and methods disclosed herein can be used in methods of diagnosing and monitoring particular autoimmune disorders and infections. The invention relates to a new diagnostic method, utilizing an antigen array for simultaneously identifying different antigens capable of activating the complement system, in a quantitative fashion; to multiplex immunoassays utilizing antigen arrays, and more particularly to systems, methods and kits for qualitative and quantitative detection of antigens activating complement in a biological sample, via the measurement of complement components deposited on antigen arrays. The invention employs the functional complement system in the biological sample tested, thereby the information gained relates to antigen recognition properties and functional consequences in the organism from which the sample was taken and relies on the ability of antigen recognition molecules, primarily antibodies to activate the complement system in the sample tested, upon binding to elements of an antigen array.